Colonic mucus-accumulating tungsten oxide nanoparticles improve the colitis therapy by targeting Enterobacteriaceae

The imbalance of gut microbiota, such as dysbiotic expansion of Enterobacteriaceae, is strongly associated with the progress of inflammatory bowel disease (IBD) via exacerbating gut inflammation and disturbing intestinal mucosal barrier. Recently, a microbiota-based strategy is an attractive paradigm for IBD therapy. Here, we explored the therapeutic potential of tungsten oxide nanoparticles (WO(3)NPs) against DSS-induced acute colitis mice. WO(3)NPs (47.9 nm in diameter) significantly reduced intestinal inflammation, attenuated bacterial translocation, restored the colonic epithelium barriers, and remodeled gut microbiota homeostasis in inflamed colon, compared with the free tungsten (sodium tungstate). The element quantification and mapping results showed WO(3)NPs could increase the adherence of tungsten with Enterobacteriaceae in colonic mucus layer, which inhibited Enterobacteriaceae growth by microbial metabolic reprogramming and ameliorate colitis. This nano-enabled approach for tungsten reduced its deposition in the main organ except for the colon thereby improve the therapeutic efficacy with good biosafety. Together, our results provide insights into the potential nanotherapeutics of WO(3)NPs against the invasion processes of micro biota in the treatment of IBD. (C) 2021 Elsevier Ltd. All rights reserved.

Automated summary

The study investigated the therapeutic potential of tungsten oxide nanoparticles in treating acute colitis, finding that they reduced intestinal inflammation, restored intestinal barriers, reshaped gut microbiota balance, and improved treatment efficacy by inhibiting Enterobacteriaceae growth and ameliorating colitis.